Wednesday, February 28, 2024

Bitcoin Moves Higher

Bitcoin has put in a nice move higher this week. I'm inserting an article from Crypto Presales, Nigeria Blocks Access to Crypto Exchanges. The main driver of the article relates to currency, as citizens try to move money out of a sliding currency, in this case the Naira, and into crypto, such as bitcoin, seeking less inflation. The government intends to block the on-line exchange of companies like Binance, Coinbase, and Kraken. Weekly chart below of Bitcoin, below. 

Tuesday, February 20, 2024

Axsome Fourth Quarter Financial Results

Axsome released their fourth quarter financial results today. Just a few highlights from the just completed impressive quarter, are below. 

  • Auvelity for MDD sales totaled $49.0 million for the quarter
  • Sunosi for narcolepsy sales totaled $22.5 million for the quarter
  • $386 million in cash on hand, end of quarter
  • AXS-12 clinical trial for cataplexy, to read out in the first quarter, 2024
  • AXS-05 clinical trial for Alzheimer's Disease Agitation, second half 2024
The only negative seen for this quarterly release is the clinical trial of AXS-05 for Alzheimer's Disease Agitation, which has been moved to be released in the second half of 2024.  Current chart of Axsome below. Thank you for reading.

Sunday, February 18, 2024

Alzheimer's Disease Agitation

Alzheimer's Disease Agitation, is an unmet medical need. Three companies have addressed potential therapy for these patients.  Otsuka and partner Lundbeck with Brexpiprazole, has already achieved FDA approval as the first and only approved drug, but carries a Black Boxed Warning. Another candidate from Otsuka again, is AVP-786. AVP-786 has yet to achieve two meaningful positive clinical trial readouts, and has two clinical trials scheduled to complete in 2026. Axsome's AXS-05 has completed one successful clinical trial known as ADVANCE-1. AVANCE-2 is scheduled to read out in the first half of 2024. If successful, the company will pursue an sNDA filing with the FDA for approval.  Click on chart below for a larger version. Thank you for reading.